Resveratrol

BACKGROUND/AIM: Resveratrol, a polyphenolic compound found in grapes, berries, and peanuts, has been linked to antioxidant, anti-inflammatory, and vasoprotective effects. Yet, evidence from randomized controlled trials (RCTs) remains inconsistent, and the quality, dosage, and cost of commercial resveratrol products vary considerably, raising uncertainty about their true efficacy. A comprehensive synthesis of its effects on obesity-related non-communicable diseases (NCDs) is therefore warranted. Given that obesity is a key driver of metabolic dysregulation underlying diabetes, cardiovascular disease, and fatty liver disease, clarifying resveratrol's potential in overweight and obese populations is of particular importance. MATERIALS AND METHODS: We systematically searched PubMed, Embase, the Cochrane Library, and Web of Science for RCTs published up to July 2025 that evaluated resveratrol supplementation in adults with obesity-related metabolic disorders or associated risk factors. Study selection and data extraction followed PRISMA 2020 guidelines. Pooled estimates were calculated using random-effects models, and heterogeneity was assessed with the I2 statistic. RESULTS: Forty RCTs involving 2551 participants were included. Resveratrol significantly reduced the homeostatic model assessment of insulin resistance (HOMA-IR), total cholesterol (TC), triglycerides (TG), low density lipoprotein (LDL) cholesterol, systolic blood pressure (SBP) and diastolic blood pressure (DBP), high-sensitivity C-reactive protein (hs-CRP), tumor necrosis factor-alpha (TNF-α), and interleukin-6 (IL-6). No consistent changes were observed for high-density lipoprotein (HDL) cholesterol, body weight (BW), body mass index (BMI), fat mass, hip circumference (BC), waist circumference (WC), aspartate aminotransferase (AST), alanine aminotransferase (ALT), gamma-glutamyl transferase (GGT), or liver fat. To our knowledge, this meta-analysis includes the largest number of RCTs to date and the most comprehensive coverage of obesity-related metabolic and inflammatory endpoints. Effect sizes varied by intervention dose and duration. CONCLUSION: Resveratrol supplementation shows modest benefits on s

In order to make clinical recommendations based on uncertain evidence, a systematic review and meta-analysis on the influence of micronutrient supplementation on preclinical and clinical reproductive outcomes was undertaken. PubMed and Scopus were searched until 12 November 2024. Parallel-grouped intervention studies with women undergoing fertility treatment with micronutrient supplementation or addition of micronutrient to in-vitro maturation media were included. The primary outcomes were oocyte maturation and chromosome aneuploidy rates, pregnancy rate, miscarriage rate, and live birth rate. Five of 1810 studies were included. In three clinical studies, 326 women underwent fertility treatment with coenzyme Q10 (CoQ10) or control treatment. CoQ10 increased oocyte retrieval and live birth rates for women diagnosed with poor ovarian response (POR; OR = 2.28), and increased the pregnancy rate for women diagnosed with POR or polycystic ovary syndrome (PCOS) (OR = 2.20 and 13.26, respectively). CoQ10 had no effect on the miscarriage rate. In two in-vitro studies, 127 women donated 241 immature oocytes which were matured with CoQ10 or resveratrol. CoQ10 increased the oocyte maturation rate (OR = 2.73), and decreased oocyte and chromosome aneuploidy rates (OR = 0.31 and 0.57, respectively) for women of advanced maternal age (AMA). Resveratrol had no effect. Women of AMA and women diagnosed with POR or PCOS gained greater benefit from CoQ10 supplementation.

BACKGROUND: The effects of resveratrol supplementation on anthropometric indices, adiponectin, and leptin levels remain inconclusive in individuals with overweight and obesity. METHOD: This systematic review and meta-analysis of randomized controlled trials (RCTs) was conducted to evaluate the effects of resveratrol supplementation on anthropometric indices, adiponectin, and leptin levels. We searched electronic databases, including Scopus, Web of Science, and PubMed, up to September 2025, to identify eligible RCTs. RESULTS: A total of 23 RCTs, involving 1005 participants, met the inclusion criteria for the meta-analysis. Resveratrol supplementation did not significantly affect body weight (WMD: -1.42 kg; 95% CI: -3.19, 0.35; P = 0.117), body mass index (BMI) (WMD: -0.47 kg/m²; 95% CI: -0.96, 0.01; P = 0.055), fat mass (FM) (WMD: 0.47 kg; 95% CI: -1.75, 2.69; P = 0.679), body fat percentage (BFP) (WMD: -0.88%; 95% CI: -1.91, 0.15; P = 0.094), fat-free mass (FFM) (WMD: 1.42 kg; 95% CI: -1.04, 3.89; P = 0.257), waist-hip ratio (WHR) (WMD: -0.00; 95% CI: -0.01, 0.00; P = 0.436), adiponectin (WMD: 1.84 µg/mL; 95% CI: -2.25, 5.95; P = 0.378), or leptin (WMD: 1.87 ng/mL; 95% CI: -3.84, 7.60; P = 0.521). However, resveratrol supplementation significantly reduced waist circumference (WC) (WMD: -1.93 cm; 95% CI: -3.10, -0.76; P = 0.001). Subgroup analyses revealed significant reductions in body weight and BMI with doses <1000 mg/day, longer interventions (≥12 weeks), and in females. Additionally, FFM increased significantly among participants aged <50 years, and leptin levels were significantly elevated in both sexes. CONCLUSION: This meta-analysis showed that resveratrol supplementation did not significantly impact most anthropometric measures and serum leptin and adiponectin in individuals with overweight and obesity. However, it led to a significant reduction in waist circumference. The PROSPERO registration number: is CRD42024497932. © 2025. The Author(s), under exclusive licence to Springer Nature Limited.

Some evidence suggests that resveratrol may have anti-obesity effects on diabetic patients; while other studies have not confirmed this claim. This study aimed to systematically review the literature and evaluate the impact of resveratrol supplementation on body weight, body mass index (BMI), waist circumference (WC), waist-to-hip ratio (WHR), and hip circumference (HC) in individuals with type 2 diabetes (T2D). We conducted comprehensive searches in electronic databases such as Web of Science, PubMed, Scopus, and the Cochrane Library up to February 2023. We included randomized controlled trials (RCTs) including adult T2D patients who received resveratrol supplementation and reported at least one anthropometric measure. Two independent researchers performed data extraction and quality assessment. We determined overall effect sizes using a random-effects model and assessed heterogeneity using the I 2 statistic and Cochrane's Q test. A total of 11 trials with 614 participants were included. The pooled effect size showed that taking resveratrol supplements significantly decreased body weight (WMD: -0.44 kg, 95% CI: -0.88 to -0.00, p = 0.048), BMI (WMD: -0.19 kg/m2, 95% CI: -0.37 to -0.01, p = 0.03), and WC (WMD: -0.80 cm, 95% CI: -1.35 to -0.24, p = 0.005). However, we did not find any significant effects on HC or WHR. This meta-analysis revealed significant reductions in body weight, BMI, and WC among T2D patients who consumed resveratrol. However, there was no significant effect on HC and WHR. Further high-quality, long-term studies are necessary to confirm these findings. © 2025 John Wiley & Sons Ltd.

BACKGROUND: The therapeutic application of dietary polyphenols in chronic obstructive pulmonary disease (COPD) management represents an emerging therapeutic paradigm in pulmonary medicine. As bioactive compounds exhibiting dual antioxidant and anti-inflammatory properties, polyphenolic derivatives demonstrate significant therapeutic potential through multimodal mechanisms targeting COPD pathophysiology - particularly in modulating redox homeostasis (GSH/GSSG ratio elevation), attenuating NF-κB-mediated inflammatory cascades, and enhancing respiratory function parameters (FEV1 improvement ≥12% from baseline). However, current clinical evidence remains inconclusive, with meta-analyses revealing heterogeneity in intervention outcomes across randomized controlled trials. This systematic investigation employs a triple-blind, placebo-controlled design to rigorously evaluate the clinical efficacy of standardized oral polyphenol supplementation in COPD patients (GOLD stages II-III), incorporating advanced biomarkers including 8-isoprostane quantification and pulmonary function trajectory analysis. METHODS: Literature on dietary polyphenols for the treatment of COPD published in PubMed, Cochrane, Medline, CNKI and other databases before December 26, 2024 (in Chinese and English) was searched. Manual screening, quality assessment and data extraction of search results were performed in strict accordance with the inclusion and exclusion criteria. Meta-analysis was performed using RevMan 5.3 software. RESULTS: The randomized controlled trials (RCTs) included in this review examined dietary supplementation with eight polyphenols-curcumin, resveratrol, anthocyanins, quercetin, salidroside, dietary beetroot juice, pomegranate juice, and adjunctive oral AKL1 treatment-across a total of 894 participants. This systematic review and meta-analysis revealed that, compared to a placebo; ① Curcumin significantly reduced systolic blood pressure (SBP) and improved FEV1(SMD=-0.82, 95%CI -1.53 to -0.11); ② Salidroside was effective in reducing thrombotic markers (TT, D-D), inflammatory factors (TNF-α) and symptom scores (CAT) (p<0.01); ③ Resveratrol significantly downregulates serum TNF-α

The influence of resveratrol on renal function was previously examined; nevertheless, the findings are inconsistent. Therefore, this systematic review and dose-response meta-analysis was performed to evaluate the effect of resveratrol on renal function. A comprehensive search was performed in Web of Science, PubMed, Scopus, and Google Scholar up to March 1st, 2025. Randomized controlled trials (RCTs) that investigated the effect of resveratrol supplementation on the urea, uric acid, blood urea nitrogen (BUN), albumin, total protein, glomerular filtration rate (GFR), and creatinine (Cr) were included. A total of 2299 participants from 31 studies were included. Meta-analysis of studies indicated that resveratrol supplementation in comparison to placebo had favorable effects on the values of BUN [weighted mean difference (WMD) = - 1.20; 95% CI: - 1.89, - 0.51 mg/dL; I2 = 84.6%; 95% CI: 77, 90%; Tau2 = 1.41; P < 0.001]. Based on the subgroup analysis, significant improvement was seen in Cr and GFR in the subgroup of participants without diabetes. Additionally, resveratrol supplementation for more than 8 weeks or at doses higher than 500 mg/d significantly elevated GFR and total protein values, respectively. However, the circulating values of albumin and uric acid were not affected by resveratrol supplementation. Although dose-response analysis was conducted for dosage and duration of intervention, no significant results were found. Resveratrol supplementation might improve GFR, BUN, creatinine, and total protein concentrations in adults. However, it did not significantly affect the circulating values of albumin and uric acid. © 2025. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.

BACKGROUND: Resveratrol, a natural polyphenol compound, possesses anti-aging, antitumor, and vascular protective properties. These attributes are believed to stem from its influence on Sirtuin 1 (Sirt1), a member of the human Sirtuin family and a nicotinamide adenine dinucleotide-dependent histone deacetylase. OBJECTIVE: The aim of this study was to quantitatively investigate the impact of resveratrol supplementation on Sirt1 levels in adults by conducting a systematic review and meta-analysis of randomized controlled trials (RCTs) involving resveratrol supplementation. METHODS: This Grading of Recommendations Assessment, Development and Evaluation-assessed systematic review involved a comprehensive search of PubMed, Embase, MEDLINE, Scopus, Web of Science, Cochrane Central Register of Controlled Trials, and Google Scholar databases using related keywords and was conducted from March 14, 2024, to April 15, 2024, to identify all RCTs investigating resveratrol's effects on Sirt1. Effect sizes were quantified as mean differences (MDs) or standardized mean differences (SMDs), with standard deviations of outcomes. An overall effect estimate was derived using a random-effects model when 2 or more studies reported similar outcomes. Statistical heterogeneity was assessed through the calculation of I2 statistics. In addition, a dose-response analysis was performed to assess potential dose-response relationships. Risk of bias was assessed using the Cochrane risk-of-bias tool for RCTs (RoB 2). Publication bias was evaluated using Begg's test and a meta-regression using the year of publication as a moderator. RESULTS: Eleven RCTs examining the effects of resveratrol on Sirt1 gene expression (4 RCTs), protein expression (5 RCTs), and serum levels (3 RCTs) were included in the meta-analysis. The results showed no significant impact of resveratrol on Sirt1 gene expression (SMD = 0.05; 95% CI -0.24 to 0.344; P = .73), protein expression (SMD = 0.3; 95% CI -0.15 to 0.77; P = .18), or serum levels (MD = -0.04; 95% CI -0.235 to 0.16; P = .7). However, subgroup analyses suggested a significant increase in Sirt1 gene expression in studies with an intervention duration of <12 weeks a

8. BJOG. 2025 Jun;132(7):867-879. doi: 10.1111/1471-0528.18106. Epub 2025 Mar 3. Polyphenols for the Prevention or Management of Preeclampsia: A Systematic Review and Meta-Analysis. Nguyen PY(1), Sanderson B(1), Makama M(1), Mills K(1), Ammerdorffer A(2), Gülmezoglu AM(2), Vogel JP(1), McDougall

BACKGROUND: The effects of resveratrol supplementation on inflammation and oxidative stress in patients with type 2 diabetes mellitus (T2DM) were controversial. A meta-analysis was performed to assess the changes in levels of inflammation and oxidative stress in patients with T2DM. METHODS: Relevant literatures before November 6, 2024 were screened through Web of Science,Embase,the Cochrane Library and other sources (ClinicalTrials, ProQuest Dissertations and Theses). The quality of the literature was evaluated according to the Cochrane Handbook of Systematic Reviews. The study quality was assessed using the risk-of-bias 2 tool and the Grading of Recommendations Assessment,Development and Evaluation (GRADE) system. Review Manager 5.3 conducted meta-analysis of the data included in the literature. RESULTS: This meta-analysis was conducted in six randomized controlled trials involving 533 participants. Our results showed that supplementation with resveratrol significantly reduced C-reactive protein levels(SMD = -1.40, 95%CI(-2.60, -0.21), P = 0.02; Level of evidence: low), lipid peroxide levels (SMD = -0.99, 95%CI(-1.36, -0.61), P < 0.00001; Level of evidence: low), 8-isoprostanes(SMD = -0.79, 95%CI(-1.16, -0.42), P < 0.0001; Level of evidence: low) and oxidative stress score (SMD = -1.62, 95%CI(-2.49, -0.75), P = 0.0003; Level of evidence: very low). In addition, compared to placebo, Supplementation with resveratrol significantly increased glutathione peroxidase levels (SMD = 0.38, 95%CI(0.03, 0.74), P = 0.04; Level of evidence:low) and catalase levels (SMD = 0.33, 95%CI(0.03, 0.63), P = 0.03; Level of evidence: low). However, no significant difference was observed in improving interleukin-6 levels (SMD = -1.35, 95%CI(-2.75, -0.05), P = 0.06; Level of evidence: very low), tumor necrosis factor α levels (SMD = -3.30, 95%CI(-7.47, 0.87), P = 0.12; Level of evidence: very low), superoxide dismutase levels (SMD = 0.39, 95%CI(-0.26, 1.04), P = 0.24; Level of evidence: very low), total antioxidant capacity levels (SMD = 0.39, 95%CI(-0.23, 1.00), P = 0.21; Level of evidence: very low) and malondialdehyde levels (SMD = -3.36, 95%CI(-10.30, 3.09), P = 0.29; Level of evide

AIMS: Postmenopausal women experience an increase in cardiovascular, sexual, and emotional changes that can significantly impact their quality of life. Although phytoestrogens offer therapeutic benefits, our understanding of resveratrol's effects remains limited. This study aims to evaluate the effects of using resveratrol on the lipid profile of postmenopausal women. DATA SYNTHESIS: We conducted a systematic review using search terms like "postmenopausal" and "resveratrol" and their synonyms. Two reviewers handled study selection and data extraction. Randomized clinical trials assessing resveratrol in post-menopausal women were included. The meta-analysis on total cholesterol levels found no significant difference between groups, Standardized Mean Difference (SMD) -0.09 (95 % Confidence Interval (CI) -0.39 to 0.22, p = 0.59; I2 = 0 %, 2 studies, low-quality evidence). No significant differences were found in high-density lipoprotein (HDL) levels, SMD 0.00 (95 % CI -0.31 to 0.31, p = 1; I2 = 0 %, 2 studies, low-quality evidence), Low-Density Lipoprotein (LCD) levels, SMD -0.10 (95 % CI -0.40 to 0.21, p = 0.54; I2 = 0 %, 2 studies, low-quality evidence), and triglyceride levels, SMD -0.12 (95 % CI -0.18 to 0.43, p = 0.43; I2 = 0 %, 2 studies, low-quality evidence). CONCLUSION: This review concludes there's limited evidence for recommendations; further studies with higher doses, longer supplementation durations, and exploration of outcomes are needed to clarify therapeutic potential.

Background. Research indicates that omega-3 fatty acids, resveratrol, astaxanthin, and coenzyme Q10 (CoQ10) possess anti-inflammatory properties, and their vascular benefits have been well-documented. This is a pilot study aimed at comprehensively evaluating the potential impact of the compound fish oil capsules on the microcirculation of multiple organs. Methods. In a triple-blind, randomized, placebo-controlled trial, 64 hypertensive patients were randomly assigned to either the compound fish oil (FO) group or the corn oil (CO) group (n = 32 per group) for a 3-week intervention. Participants were required to consume 2 capsules of the corresponding oil daily. The microcirculation functions of the heart, skin, and brain were examined by transthoracic Doppler echocardiography (TTDE), laser Doppler flowmetry (LDF), and magnetic resonance imaging (MRI), respectively. Data were primarily analyzed according to an intention-to-treat approach. Findings. In the left anterior descending artery (LAD), the end-diastolic velocity (EDV) and peak diastolic velocity (PDV) significantly increased in the FO group. The mean differences in change were 1.95 (0.13, 3.77; p = 0.036) and 2.95 (0.48, 5.41; p = 0.020), respectively. The resistance index (RI) showed a decreasing trend in the FO group, but the result was non-significant (p = 0.071). No significant differences were observed in blood pressure, brain and skin microcirculation parameters among the different groups. Interpretation. Compound fish oil capsules did not significantly improve RH. But compound fish oil capsules improved EDV and PDV levels in the LAD of hypertensive patients.

PURPOSE: Knee osteoarthritis (OA) and postural imbalance are interlinked, increasing fall risk in older adults. The effective therapeutic approach remains unclear. OBJECTIVE: To investigate how resveratrol, a natural stilbene compound, influences balance disturbances in individuals with knee OA METHOD: In a randomized double blind clinical trial, 129 patients with OA were allocated to receive either placebo (n = 67) or resveratrol at a daily dose of 500 mg (n = 62) for 18 weeks. Assessments included Oxford Knee Score (OKS), WOMAC index, knee flexion range of motion (ROM), gait speed, handgrip strength, balance scores, and plasma concentrations of SIRT1 and C-reactive protein (CRP), recorded at baseline and again after 18 weeks. RESULTS: Resveratrol significantly improved balance, gait speed, knee ROM, HGS, and reduced pain during walking and WOMAC scores (all p < 0.05), without affecting OKS or resting pain. Plasma SIRT1 increased, and CRP decreased in the resveratrol group. SIRT1 levels correlated strongly with balance scores post-treatment (r²=0.322, p < 0.0001), more than in placebo (r²=0.084, p = 0.017) or baseline values. CONCLUSION: Resveratrol alleviated OA symptoms and postural imbalance, potentially through anti-inflammatory effects mediated by elevated plasma SIRT1.

Menopause increases cardiometabolic risk, partly by reducing the protective effects of estrogens and inducing gut microbiota dysbiosis, which can promote the production of atherogenic metabolites such as trimethylamine N-oxide (TMAO). Polyphenols may reduce TMAO levels, though interindividual variability limits reproducibility. We compared urinary and serum TMAO levels, and urinary trimethylamine (TMA) and dimethylamine (DMA) levels between healthy women of reproductive age (Pre-M, n = 120) and non-medicated postmenopausal women (Post-M, n = 90) using UPLC-QqQ-MS/MS. In Post-M women, we conducted a randomised, placebo-controlled crossover study to evaluate the effects of a polyphenol-rich extract mixture containing pomegranate, Polygonum cuspidatum, and red clover (sources of ellagitannins, resveratrol, and isoflavones) on TMAO, TMA, and DMA in the whole group and after metabotyping. Because medication is common in Post-M women due to age and cardiometabolic risk, trials in non-medicated participants are challenging, yet avoiding drug-diet interactions allows clearer attribution of dietary effects. Urinary TMAO and DMA levels were higher in Post-M than in Pre-M. No changes were observed in serum TMAO. However, the intervention reduced urinary TMAO and DMA versus baseline and placebo. The effects varied by metabotype. TMAO reduction was significant in urolithin A metabotype (UMA), equol producers (EP), and lunularin non-producers (LNP). Reductions and effect sizes were most pronounced in the metabotype clusters MC3 (UMA + EP + LP) and MC7 (UMA + EP + LNP), which represented 39% of participants. DMA decreased selectively in UMA. No correlations were found between TMAO or DMA changes and BMI, age at menopause onset, or years since menopause. These findings show that polyphenol supplementation reduces urinary TMAO in a metabotype-dependent manner and support metabotyping as a precision-health strategy to mitigate cardiometabolic risk after menopause.

Background/Objectives: Interindividual variability in polyphenol metabolism may help explain the inconsistent effects of polyphenol intake on health outcomes. This study compared, for the first time, (i) polyphenol-related gut microbiota metabotypes (urolithins: UM0, UMA, UMB; equol: EP, ENP; lunularin: LP, LNP) and their clusters (MCs) in non-medicated premenopausal (Pre-M) and postmenopausal (Post-M) women and (ii) the impact of an 8-week intake of a polyphenol-rich plant extract mixture (PPs) on the quality of life (QoL) of Post-M. Methods: Polyphenol metabotypes were determined in urine via UPLC-QTOF-MS after a 3-day intake of PPs containing resveratrol, pomegranate (ellagitannins and ellagic acid), and red clover (isoflavones) in Pre-M (n = 120) and Post-M (n = 90) women. QoL was assessed with the short-form Cervantes Scale in a randomized, placebo-controlled crossover trial (8-week PPs vs. placebo), completed by 78 Post-M participants. Results: At baseline, Pre-M and Post-M women showed only minor differences in metabotype and MC distributions linked to menopausal status. MC3 (UMA+EP+LP) predominated in Pre-M, while MC7 (UMA+EP+LNP) was most frequent in Post-M. PPs intake in Post-M women led to modest shifts in metabotype and MC distributions toward Pre-M patterns. Quantitative metabolite production was comparable between groups, except for equol, which showed a median 2.8-fold increase after PPs intake in EP Post-M women. Clinically meaningful improvements (score reduction ≥ 6.7 points) in QoL were observed in the Psychic domain in EP women (28%, p = 0.039) and in the Menopause and Health domain, specifically in EP (24.1%, p = 0.004), MC3 (22.5%, p = 0.043), and MC4 (UMB+EP+LP; 41.3%, p = 0.022), were mainly driven by a reduction in hot flashes (p = 0.001). Conclusions: These findings support metabotyping as a tool to guide targeted dietary strategies and enhance QoL through precision health in Post-M women.

PURPOSE: Osteoarthritis (OA) is a debilitating disease of joints. Currently, there are no optimal treatment options to cure OA. OBJECTIVE: To determine whether resveratrol treatment can improve physical function in knee OA patients. Trial design This investigation employed a single center-based, double-blinded, randomized, placebo-regulated clinical trial structure. METHODS: We led a 12-week clinical study involving 137 knee OA patients, aged 63-73. Participants were divided to form a placebo-taking group (n = 70) and an intervention group receiving 500 mg/day of resveratrol (n = 67). Data collection occurred at the start and after 12 weeks. Key study outcomes included: pain intensity (VAS), Oxford Knee Score (OKS), WOMAC index score, knee flexion range of motion (ROM), short physical performance battery (SPPB), handgrip strength (HGS), gait velocity, and levels of SIRT1, C-reactive protein (CRP), and 8-isoprostanes. RESULTS: After accounting for dropouts, 122 patients were analyzed (placebo: n = 65, resveratrol: n = 57). Resveratrol treatment significantly reduced pain intensity and WOMAC scores, while increasing OKS scores, ROM, gait velocity, HGS, and overall SPPB performance (p < 0.05). In addition, OA patients on resveratrol showed higher plasma SIRT1 and lower 8-isoprostanes levels (p < 0.05). The correlation analysis demonstrated robust associations between changes in plasma SIRT1 and improvements in OKS scores (r2 = 0.204, p = 0.0005), SPPB total (r2 = 0.223, p = 0.0001), HGS (r2 = 0.119, p = 0.008), and gait speed (r2 = 0.138, p = 0.004). CONCLUSION: Overall, resveratrol supplementation enhances the physical capabilities of OA patients by increasing SIRT1 levels. Further research is warranted to more fully define resveratrol's impact on knee OA. TRIAL REGISTRATION: This investigation was retrospectively registered on the Open Science Framework (OSF), ensuring transparency and accessibility of the study protocol and outcomes. Registration date (21st April 2025) and URL for protocol ( https://osf.io/registries/my-registrations ). © 2025. The Author(s), under exclusive licence to Springer Nature Switzerland AG.

Knee osteoarthritis (OA) and frailty share pathophysiological processes and are leading causes of disability in the geriatric population; however, effective interventions remain elusive. To investigate the effects of resveratrol, on knee OA and frailty, a double-blind, placebo-controlled, randomised clinical trial was conducted over 16 weeks in patients with knee OA. 123 patients aged 63-75 years were randomised into placebo (n = 64) and resveratrol (500 mg/d; n = 59) groups. Outcome variables assessed at baseline and 16 weeks included OA evaluation using the Oxford knee score (OKS), Western Ontario and McMaster Universities (WOMAC) index, knee flexion range-of-motion (ROM), and gait speed; frailty using Fried's scale; handgrip strength (HGS); and plasma SIRT1. Resveratrol reduced frailty, pain during walking, and WOMAC scores, and improved OKS and HGS (all p < 0.05), without affecting ROM or gait speed. Patients receiving resveratrol had higher SIRT1 levels associated with frailty scores. Increased SIRT1 is linked to improved OA symptoms and reduced severity.

Polycystic ovary syndrome (PCOS) is a common endocrine disorder affecting women of reproductive age characterized by metabolic dysfunction, insulin resistance, and hormonal imbalance. Metformin, a well-known insulin sensitizer, and Resveratrol, an antioxidant polyphenol, have both shown promise in managing the metabolic and reproductive features of PCOS. This study evaluates the effects of Resveratrol alone and in combination with Metformin on clinical, metabolic, endocrine and reproductive parameters in women with PCOS over a 6-month period. A randomized controlled trial was conducted with PCOS women, who were assigned to two groups: one receiving Resveratrol monotherapy (33 participants) and the other receiving a combination of Resveratrol plus Metformin (30 participants). Treatment effects on demographic, anthropometric, clinical, endocrine and metabolic parameters were assessed at baseline, after 3 months and 6 months. Following dropouts and adverse effects, 25 participants were analyzed in each group for the final evaluation. statistical analysis was performed using SPSS version 26., employing t-tests, repeated measures ANOVA, and chi-square test. Where baseline imbalances existed, Analysis of Covariance (ANCOVA) was additionally performed to adjust for pre-treatment differences., with p < 0.05 considered significant. Both treatment groups showed significant within-group improvements over 6 months. Resveratrol monotherapy led to marked improvements in BMI, ovarian volume, Ferriman-Gallwey Score (FGS), LH levels, and quality of life (p < 0.001). The combination of Resveratrol with Metformin showed significantly reductions in fasting glucose (p = 0.002), BMI (p = 0.005), and oxidative stress marker MDA (p < 0.001). Menstrual regularity improved in both groups, with 96% of participants in the Resveratrol group and 85% in the combination group reporting regular cycles at 6 months. Perceived stress levels improved in both groups, with a shift toward lower stress categories. Absolute change revealed significantly higher improvements in quality of life and ovarian morphology in the Resveratrol group, while metabolic parameters improved more in the combination grou

OBJECTIVE: Smoking patients demonstrate an elevated risk of periodontitis development and respond poorly to periodontal therapy as compared to nonsmokers, and resveratrol (RSV) demonstrated a positive effect in the reduction of periodontitis progression in both animal and clinical trials. However, to the authors' knowledge, no clinical study has assessed the impact of resveratrol under smoking conditions. Thus, this trial aimed to evaluate the effect of systemic administration (SA) of RSV adjunct to full-mouth ultrasonic debridement (FMUD) of periodontitis smoking patients (PSP). MATERIALS AND METHODS: Thirty-eight individuals were randomly assigned to two groups:Placebo ( n = 19) -FMUD and placebo for 180 days; RSV ( n = 19) FMUD and RSV (500 mg/day) for 180 days. Clinical and immunoinflammatory outcomes were assessed at baseline, 3-, 6-, and 12-months post-therapy, and microbiological outcomes were evaluated at baseline, 3-, 6- months post-therapy. RESULTS: RSV appeared to induce lower PD [2.96 (0.41) - 3 months; 2.85 (0.40) - 6 months; 2.80 (0.35)- 12 months], CAL [4.02 (0.90) - 3 months; 4.04 (0.81) - 6 months; 3.87 (0.78) - 12 months], and PMG [2.20 (0.56) - 3 months; 2.28 (1.14) - 6 months; 2.32 (3.27) - 12 months] readings as compared to Placebo [PD: 3.22 (0.51) - 3 months; 3.07 (0.42) - 6 months; 3.02 (0.42) - 12 months; CAL: 4.43 (0.99) - 3 months; 4.24 ((0.89) - 6 months; 4.39 (0.93) - 12 months; PMG: 2.50 (0.50) - 3 months; 2.53 (0.45) - 6 months; 2.67 (0.46) - 12 months] throughout the time (p < 0.05). The concentration of Aggregatibacter actinomycetemcomitans (Aa) was significantly higher in moderate [2.29 (1.10); 1.61 (1.02) for PL and RSV, respectively] and deep PD [2.39 (1.14); 1.73 (0.90) for PL and RSV respectively] at 3 months for the Placebo group (p < 0.05). Additionally, Aa levels were lower at 6 months in the deep sites for the RSV group (p < 0.05) [1.77 (0.94); 2.23 (1.08) for PL and RSV, respectively]. Immunoinflammatory analysis showed lower levels of IL-1β at 3-month periods in deep sites in the RSV group [92.6 ± 84.2; 35.36 (52.92) for PL and RSV, respectively] and lower concentrations of IL-6 in the RSV group at 3 and 12 months in bo

Polycystic ovary syndrome (PCOS) is a multifactorial endocrine disorder in women. Oxidative stress (OS) plays a pivotal role in the pathogenesis of PCOS. Resveratrol, as a natural polyphenol, has several beneficial therapeutic effects for women with PCOS. In this study, we investigated the antioxidant effect of resveratrol on OS markers in follicular fluid (FF) and granulosa cells (GCs) of patients with PCOS. A total of fifty-six patients with PCOS were randomly assigned to receive 800 mg/day of resveratrol or placebo for 60 days. The main focus was on evaluating OS markers, such as malondialdehyde (MDA) and total thiol (sulfhydryl) content in FF, along with assessing the levels of total antioxidant capacity (TAC) and total oxidant status (TOS) in GCs. Additionally, secondary outcomes included measuring the expression of genes associated with OS responses (Manganese superoxide dismutase (Mn-SOD), catalase (CAT), and uncoupling protein 2 (UCP2)), as well as the expression of UCP2 protein in granulosa cells. Compared with the placebo group, resveratrol reduced MDA and conversely significantly increased total thiol (P = 0.6694 and P = 0.0318, respectively) in FF. Resveratrol significantly reduced TOS and oxidative stress index (OSI) (P = 0.0299 and P = 0.0144, respectively) and significantly increased TAC (P = 0.0484) in GCs. There were significant increases in CAT and UCP2 expression after resveratrol consumption (P = 0.0158 and P = 0.0004, respectively). Although resveratrol increased Mn-SOD expression (P = 0.0914), its effects were not statistically significant. Resveratrol significantly affected UCP2 protein levels (P = 0.0030). These findings suggested that 60 days of supplementation with 800 mg/day resveratrol improves markers of OS in the FF and GCs of patients with PCOS. Trial registration number: http://www.irct.ir ; IRCT20221106056417N1; 2023 February 09. © 2025. The Author(s), under exclusive licence to Society for Reproductive Investigation.

Hypertension is a debilitating disease affecting the population worldwide. Novel therapeutic strategies that complement the current management of hypertension will reduce the disease burden. Our randomized, cross-over, double-blinded, placebo-controlled trial studied the efficacy of plant polyphenol resveratrol (trans-3, 5, 4'-trihydroxystilbene) in managing blood pressure in pre-hypertensive and stage-1-hypertensive patients. Participants with pre-hypertension (diastolic and systolic blood pressure (BP), 80-89 mmHg and 120-139 mmHg, respectively) and 30 participants with stage-1-hypertension (diastolic and systolic BP, 90-99 mmHg and 140-159 mmHg, respectively) were assigned to receive 500 mg resveratrol, twice daily for 4 weeks, orally) or placebo twice daily for 4 weeks) in a 2 × 2 cross-over design (4 weeks treatment-4 weeks washout-4 weeks treatment). The BP of each participant was recorded every week during the study. Data analysis using the multivariable model revealed that resveratrol's effects on systolic and diastolic BP were not statistically significantly superior to those of placebo. Nitric oxide (NO) was considerably higher in the resveratrol-treated group than in the placebo-treated group. In this preliminary study, Resveratrol supplementation for a short duration enhances nitric oxide production but does not significantly lower blood pressure in pre-hypertension or stage 1 hypertension patients. This finding remains exploratory and needs confirmation through larger, long-term clinical trials. Trial registration: IRCT201407078129N7, first trial registration date: 15/08/2014. © 2025. The Author(s).

Erratum in Int J Mol Sci. 2026 Sep 21;27(18):8402. doi: 10.3390/ijms27188402. This study aimed to investigate the effects of resveratrol (RES) and carboplatin (CPT), alone and in combination, on cell viability, apoptosis, cell cycle progression, mitochondrial function, and oxidative stress in Y79 retinoblastoma (RB) cells. Particular emphasis was placed on evaluating the synergistic potential of the combination and elucidating the interconnected molecular mechanisms underlying its anticancer effects. Y79 cells were treated with RES, CPT, and their combinations. Cell viability and synergy were assessed using the MTT assay and combination index (CI) analysis. Apoptosis (annexin V/PI), cell cycle distribution (propidium iodide (PI) staining), intracellular ROS production (DCFH-DA), and mitochondrial membrane potential (JC-1) were evaluated by flow cytometry. ROS dependency was further examined using N-acetylcysteine (NAC) pretreatment. Expression levels of apoptosis- and cell cycle-related genes (BAX, BCL-2, CASP3, CASP9, CCNB1, and CDK1) were analyzed by RT-qPCR. Cytoskeletal alterations were assessed by immunocytochemistry. In addition, the antitumor effects of the combination were validated in a three-dimensional (3D) tumor spheroid model. RES and CPT reduced cell viability in a dose- and time-dependent manner and demonstrated synergistic effects (CI < 1) at selected concentrations. Combination treatment significantly increased apoptosis, induced G2/M phase arrest, enhanced ROS accumulation, and promoted mitochondrial depolarization compared with single-agent treatments. NAC pretreatment attenuated ROS generation and partially restored cell viability, supporting a contributory role of oxidative stress in combination-induced cytotoxicity. At the transcriptional level, the RES + CPT combination significantly increased the BAX/BCL-2 ratio and upregulated CASP3 and CASP9 expression, while downregulating CCNB1 and CDK1, consistent with mitochondrial apoptotic activation and G2/M arrest. Immunocytochemical analysis revealed pronounced cytoskeletal disruption and apoptotic morphology in the combination group. Importantly, in the 3D spheroid model, co-treatment markedl

In this study, the effect of a combination of Rosmarinus officinalis and Salvia officinalis essential oils (EOs) was evaluated. The chemical profile of EOs was determined by Gas Chromatography/Mass Spectrometry (GC/MS). The antibacterial effect of EOs alone was evaluated by the broth micro-dilution method, and the antioxidant activity was determined by 2,2-Diphenyl-1-picrylhydrazyl (DPPH) free radical scavenging and Ferric Reducing Antioxidant Power (FRAP) methods. The antioxidant and antibacterial interaction of the combination of EOs was evaluated through the determination of the fractional inhibitory concentration index (FICI) using the checkerboard method. The anti-aging activity of R. officinalis, S. officinalis, and their combination in a 1:1 (w/w) ratio was evaluated on SIRT1, SIRT3, and hTERT promoters in the human keratinocyte cell line HaCaT. The GC/MS analysis revealed that R. officinalis EO was dominated by 1,8-cineole (28.43% ± 0.32%) and α-pinene (26.62% ± 0.53%). α-thujone (23.98% ± 0.17%), α-pinene (17.59% ± 0.02%), camphor (15.84% ± 0.1%), and 1,8-cineole (15.76% ± 0.11%) were found as the main constituents of S. officinalis EO. Regarding the antioxidant and antibacterial activities, the results showed that R. officinalis EO tested alone showed significant efficacy. The results showed interesting synergistic effects in scavenging DPPH radical (FICI = 0.75) and in ferric reducing power (FICI = 0.50). Moreover, this combination exhibited a synergistic effect against E. hirae (FICI = 0.38), S. aureus (FICI = 0.63), and E. coli (FICI = 0.75), while the additive effect was shown against P. aeruginosa (FICI = 1). The expression level of the SIRT1 promoter in HaCaT cells treated with R. officinalis EO and its combination with S. officinalis EO is significantly higher than that of resveratrol. The results of endogenous SIRT3 expression revealed that the individual EOs and their association induced strong activity, while the strong hTERT promoter expression level was found when the HaCaT cells were treated with R. officinalis EO. © 2026 Wiley‐VHCA AG.

Breast cancer (BC) remains the most diagnosed malignancy among women worldwide, with approximately 2.3 million new cases and over 670,000 deaths reported annually. Resistance to conventional chemotherapeutic agents and treatment-related toxicity remain major challenges in BC management. Resveratrol, a naturally occurring polyphenol, has been proposed as a potential modulator of chemotherapy response; however, comparative evidence regarding its interaction with different classes of chemotherapeutic agents is limited. This study aimed to comparatively assess the effects of resveratrol on the cytotoxic, antiproliferative, and apoptotic responses induced by adriamycin, taxol, and cisplatin in MCF-7 BC cells. MCF-7 cells were treated with adriamycin, taxol, cisplatin, and resveratrol, either alone or in combination, across multiple concentrations for 24, 48, 72, and 96 h. Cell viability was evaluated using the trypan blue exclusion assay. Cellular proliferation was assessed via BrdU incorporation, while apoptosis and cell death profiles were analyzed using Annexin V staining and flow cytometry. Exposure to individual chemotherapeutic agents induced a significant time- and dose-dependent reduction in MCF-7 cell viability (p < 0.001). Resveratrol co-treatment further modulated chemotherapy-induced cytotoxicity in an agent- and time-dependent manner. Combination treatments markedly suppressed DNA synthesis compared with single-agent exposure (p < 0.01) and significantly increased apoptotic cell populations. Flow cytometric Annexin V/PI analysis demonstrated that early apoptotic cells ranged from 3.2-11.3% in single-agent treatments and increased to 0.04-50.4% in resveratrol-based combination groups. Similarly, late apoptotic/secondary necrotic cell fractions increased from 4.1-4.4% in single-agent treatments to 2.1-69.9% following combination therapy, indicating a substantially higher overall cell death response in selected treatment conditions. This study demonstrates that resveratrol modulates the cytotoxic and apoptotic responses of MCF-7 BC cells to adriamycin, taxol, and cisplatin in an agent- and time-dependent manner. The findings indicate that resveratrol acts a

BACKGROUND/AIM: Although cisplatin is a standard treatment for lung cancer, its effectiveness is often limited by tumor chemoresistance and severe side effects, driving the search for approaches that can restore drug sensitivity. Resveratrol (Res) exhibits anticancer properties, but its clinical application is hindered by poor stability and low bioavailability. This study investigated the chemosensitization effect of YI-7, a Res derivative with modified pharmacophore benzyloxy substitutions that sensitized to p53-dependent apoptosis triggered by cisplatin in human lung cancer cells. MATERIALS AND METHODS: The IC50 of YI-7 in A549 human lung cancer cells was determined using the MTT viability assay. Cell proliferation was further examined using a colony formation assay. Chemosensitizing effects were assessed by pretreating cells with cisplatin (25 μM), followed by YI-7, and analyzing cell viability (MTT), nuclear staining (Hoechst 33342/PI), and apoptosis-associated proteins using western blot. RESULTS: YI-7 exhibited moderate cytotoxicity in A549 cells (IC50 137.90±11.48 μM) and dose-dependently inhibited colony formation, with marked suppression at 50 μM. Moreover, YI-7 pretreatment synergistically enhanced cisplatin cytotoxicity in A549 cells, with Combination Index (CI) values <1 and markedly increased apoptosis, particularly at the 2:1 (YI-7:cisplatin) ratio. Mechanistically, the combination strongly up-regulated p53 expression while suppressing Akt signaling compared with either treatment alone. CONCLUSION: The Res derivative YI-7 potentiates cisplatin-induced apoptosis in human lung cancer cells through increased p53 expression and suppression of the Akt signaling pathway.

Background/Objectives: Although curcumin (CUR) and resveratrol (RSV) are natural polyphenolic compounds with reported anticancer and anti-inflammatory properties, their combined anticancer effects in melanoma cells remain incompletely characterized. This study aimed to evaluate the anticancer efficacy of CUR and RSV, individually, and in combination, in melanoma cells compared to normal melanocytes. Methods: Cell viability and intracellular ATP levels were quantified, and dose-response analyses performed. Cellular morphology and nuclear alterations were examined by phase-contrast microscopy and DAPI staining. Cell cycle distribution and apoptosis were analyzed by Muse™ Cell Analyzer with dedicated assay kits. Survival- and death-related signaling proteins were evaluated by Western blotting. Results: Combined treatment with CUR (60 μM) and RSV (40 μM) for 48 h synergistically reduced melanoma cell viability and markedly depleted intracellular ATP levels, while exerting minimal cytotoxic effects on normal melanocytes. CUR/RSV co-treatment induced pronounced morphological and nuclear alterations, significantly increased apoptotic cell populations, and modulated key signaling pathways regulating cell survival and programmed cell death in melanoma cells. Conclusions: These findings demonstrate that combined CUR and RSV treatment exerts enhanced, melanoma-selective anticancer activity while sparing normal melanocytes. The results provide a strong experimental rationale for further in vivo validation of CUR/RSV-based combination strategies as a potential therapeutic approach for melanoma.

Nanotechnology has emerged as an innovative tool capable of overcoming the limitations of traditional drug delivery systems, by enabling enhanced drug solubility and stability, controlled drug release, and improved drug targeting. Additionally, nanosystems can allow the co-encapsulation of multiple drugs simultaneously, harnessing their synergistic pharmacological effects, leading to increased therapeutic efficacy and safety. The purpose of this review is to critically analyze studies that have developed triple drug-loaded nanosystems, exploring various different nanoplatforms, such as polymeric nanoparticles, lipid nanoparticles, microcapsules, nanoemulsions, nanoemulgels, thermosensitive hydrogels, and nanocomposite hydrogels. Triple drug co-encapsulation has been achieved for non-steroidal anti-inflammatory drugs such as indomethacin, analgesic and antipyretic drugs such as paracetamol, immunosuppressant drugs such as methotrexate, antiretroviral drugs such as efavirenz, lopinavir, ritonavir, and tenofovir, antibacterial drugs such as amoxicillin and clarithromycin, antiulcer drugs such as omeprazole and famotidine, ion channel antagonists such as lomerizine hydrochloride, oxidized adenosine triphosphate, and zonampanel monohydrate, photosensitive molecules such as indocyanine green, genetic material such as MMP-9 siRNA, enzymes such as catalase, and/or plant-derived bioactive compounds such as curcumin, resveratrol, sinomenine, and thymoquinone. These molecules' triple co-encapsulation into nanometric formulations has led to controlled and sustained drug release, extended circulation time, enhanced bioavailability, and reduced systemic toxicity, with an overall improvement in drug targeting and therapeutic outcomes in rheumatoid arthritis, psoriasis and other inflammation-based conditions, HIV and Helicobacter pylori infection, and trauma-induced central nervous system secondary degeneration, ultimately opening a door for improved patient compliance due to simplified dosing regimens.

Pathogen-induced pneumonia represents a major global health threat, owing to its high morbidity and mortality. Conventional antibiotic therapies are increasingly constrained by limited efficacy and the growing prevalence of antimicrobial resistance, highlighting the urgent need for innovative therapeutic strategies capable of concurrently targeting multiple pathogenic mechanisms. In this study, we developed a carrier-free nanomedicine that co-delivers two natural compounds with synergistic pharmacological activity. Using a self-assembly approach, Baicalein (BAI) and Resveratrol (RES) were formulated into stable BAI-RES nanoparticles (BR NPs), designed to enhance aqueous solubility and improve therapeutic outcomes. BR NPs demonstrated preferential accumulation in pulmonary macrophages of pathogen-infected mice, and enabled pH-responsive drug release within the inflammatory microenvironment. Mechanistically, BR NPs modulated inflammatory and immune responses by suppressing M1 macrophage polarization, reducing excessive neutrophil infiltration, and mitigating oxidative stress through the regulation of critical signaling pathways, such as Toll-like receptor, TNF, and HIF-1 pathways. These findings indicate that carrier-free BR nanoparticles exhibit synergistic effects, macrophage-targeting and controlled-release properties, as well as multi-target and multi-pathway therapeutic benefits, thus offering a novel and promising strategy for the treatment of pneumonia induced by pathogens. © 2026 John Wiley & Sons Ltd.

AIMS: This study investigates the individual and synergistic antibacterial and antibiofilm effects of nisin, resveratrol, naringenin, and saponins against Salmonella enterica subsp. enterica serovar Typhimurium ATCC 14028. The objective is to identify safe, effective compound combinations to combat Salmonella persistence in food processing environments, which is often caused by biofilm formation. METHODS AND RESULTS: Using broth microdilution, checkerboard synergy testing, and biofilm/motility assays, the antimicrobial effects were evaluated. Molecular docking and qPCR provided mechanistic insights. Naringenin and resveratrol demonstrated significant antibacterial and antibiofilm activities, especially when combined. The resveratrol-naringenin combination produced the strongest synergistic effect (Fractional Inhibitory Concentration Index (FICI) value of 0.1875), effectively inhibiting bacterial growth and biofilm formation. Molecular analyses revealed this combination targets key proteins (e.g. BcsA, CsgD) and significantly downregulates genes for biofilm formation, quorum sensing, and motility. CONCLUSIONS: The combination of resveratrol and naringenin is a promising natural strategy for controlling Salmonella. Its synergistic action impairs bacterial viability and disrupts biofilm by targeting essential proteins and downregulating key virulence genes. © The Author(s) 2025. Published by Oxford University Press on behalf of Applied Microbiology International.

Lung cancer remains a leading cause of cancer-related mortality worldwide, with therapeutic resistance and toxicity limiting the effectiveness of conventional treatments. Natural compounds have attracted significant interest as adjuncts to modern oncology owing to their ability to modulate multiple oncogenic pathways with comparatively low toxicity. Among these, genistein (GEN), piperine (PIP), and resveratrol (RES) represent particularly promising candidates. GEN, a phytoestrogen, exerts antiproliferative and pro-apoptotic effects through phosphoinositide 3-kinase/protein kinase B (PI3K/Akt), mitogen-activated protein kinase (MAPK), and NF-κB (Nuclear Factor kappa B) signaling. PIP, an alkaloid, not only demonstrates cytotoxicity and cell-cycle arrest but also improves the bioavailability of co-administered therapeutics. RES, a polyphenolic compound, regulates AMP-activated protein kinase (AMPK), PI3K/Akt, and MAPK pathways, inhibits angiogenesis and metastasis, and sensitizes cancer cells to chemotherapy. Synergistic combinations of these phytochemicals have shown enhanced apoptotic responses and significantly reduced IC50 values in cancer, underscoring their potential as multitargeted therapeutic agents. Despite encouraging preclinical and early clinical findings, challenges such as poor solubility and bioavailability hinder clinical translation. This review critically explores their synergistic effects while highlighting the challenges in translating these findings into clinical applications for lung cancer. By elucidating the underlying molecular mechanisms and therapeutic synergy, these natural compounds emerge as promising adjuncts for lung cancer therapy, warranting further mechanistic and clinical investigation. © 2025 Wiley‐VCH GmbH.

AIMS: Polymyxins are generally recommended to be used in combination with other antibiotics for improving their antibacterial effects. As for treating carbapenem-resistant Acinetobacter baumannii infections, which antibiotic is the best option for polymyxin B-based combination therapy is still under debate. Resveratrol, a natural compound that can be well-tolerated by the human body, may have potential value in the polymyxin B-based combination therapy against carbapenem-resistant A. baumannii infections. METHODS AND RESULTS: With checkerboard assays and time-killing studies, we have found that resveratrol increased the sensitivity of carbapenem-resistant A. baumannii to polymyxin B and enhanced the bactericidal activity of polymyxin B against carbapenem-resistant A. baumannii. With biofilm formation studies, we have confirmed that resveratrol potentiated the antibiofilm activity of polymyxin B and improved its bactericidal activity against the bacterial cells with established biofilms. CONCLUSIONS: Resveratrol potentiates the antibiofilm and antibacterial activity of polymyxin B against carbapenem-resistant A. baumannii. Polymyxin B used in combination with resveratrol may have better clinical efficacy than polymyxin B monotherapy in the treatment of carbapenem-resistant A. baumannii infections. © The Author(s) 2025. Published by Oxford University Press on behalf of Applied Microbiology International. All rights reserved. For commercial re-use, please contact [email protected] for reprints and translation rights for reprints. All other permissions can be obtained through our RightsLink service via the Permissions link on the article page on our site-for further information please contact [email protected].